health
FDA warns manufacturer that billionaire's claims about cancer drug Anktiva are misleading
Updated on: March 25, 2026 / 6:09 AM EDT / CBS/AP
TL;DR
- The FDA has warned ImmunityBio that statements made by Dr. Patrick Soon-Shiong about Anktiva are misleading.
- The FDA determined that a TV ad and a podcast episode promoting Anktiva are false or misleading and promote unapproved uses.
- Anktiva is approved for a hard-to-treat form of bladder cancer, but Soon-Shiong claimed it could treat, cure, or prevent other cancers.
- The FDA stated that drug promotions must provide a balanced view of risks and benefits, which the podcast failed to do.
- ImmunityBio shares fell more than 21% after the FDA letter was posted.
- The company has 15 days to correct the problems and respond to the FDA.